PROMUS(R) Element(TM) Stent Approved for Use in Diabetic and Heart Attack Patients in CE Mark Countries

NATICK, Massachusetts, September 21, 2010 - Boston Scientific Corporation (NYSE: BSX) today announced that
its PROMUS(R) Element(TM) Everolimus-Eluting Coronary Stent System has
received CE Mark approval for use in patients with diabetes[1] and those
experiencing an acute myocardial infarction (AMI), or heart attack.

"We are pleased to receive these expanded indications for the
high-risk diabetic and AMI patient groups," said Keith D. Dawkins, M.D.,
Senior Vice President and Chief Medical Officer for Boston Scientific's
Cardiology, Rhythm and Vascular Group. "The platinum chromium PROMUS Element
Stent has been well received by physicians since its launch last year in CE
Mark countries, and these new indications are important additions, especially
as the prevalence of diabetes continues to increase dramatically worldwide."

Boston Scientific is a leader in the treatment of
cardiovascular disease and has the broadest offering of drug-eluting stents
and the greatest number of specific patient indications.

The PROMUS Element Stent features a novel platinum chromium
alloy and innovative stent design, which combine to offer greater radial
strength and flexibility while reducing stent recoil. The stent geometry
helps create consistent lesion coverage and drug distribution while improving
deliverability, which is enhanced by an advanced catheter delivery system.
The higher density platinum chromium alloy provides superior visibility while
permitting thinner struts compared to prior-generation stents[2].

The Company received CE Mark approval for the PROMUS Element
Everolimus-Eluting Stent System in October 2009 and for the TAXUS(R)
Element(TM) Paclitaxel-Eluting Stent System in May, which included a specific
indication for the treatment of diabetic patients. Both Element systems
incorporate the same platinum chromium alloy, innovative stent design and
advanced catheter delivery system.

In the U.S., the Company expects Food and Drug Administration
approval for the TAXUS Element Stent System in mid 2011 and for the PROMUS
Element Stent System in mid 2012. In Japan, the Company expects approval for
the TAXUS Element Stent System in late 2011 or early 2012 and for the PROMUS
Element Stent System in mid 2012.

In the U.S., the TAXUS Element Stent and the PROMUS Element
Stent are investigational devices and are limited by applicable law to
investigational use only and are not available for sale.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. Forward-looking statements may be
identified by words like "anticipate," "expect," "project," "believe,"
"plan," "estimate," "intend" and similar words. These forward-looking
statements are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements include,
among other things, statements regarding new product launches and launch
cadence, regulatory approvals, clinical trials, product performance and
competitive offerings. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual results
could vary materially from the expectations and projections expressed or
implied by our forward-looking statements. These factors, in some cases, have
affected and in the future (together with other factors) could affect our
ability to implement our business strategy and may cause actual results to
differ materially from those contemplated by the statements expressed in this
press release. As a result, readers are cautioned not to place undue reliance
on any of our forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; intellectual
property; litigation; financial market conditions; and, future business
decisions made by us and our competitors. All of these factors are difficult
or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A -
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A -
Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

    ---------------------------------

    [1] For patients with concomitant diabetes mellitus.
    [2] Based on bench testing. Data on file with Boston Scientific.

    CONTACT:
    Paul Donovan
    +1-508-650-8541 (office)
    +1-508-667-5165 (mobile)
    Media Relations
    Boston Scientific Corporation

    Larry Neumann
    +1-508-650-8696 (office)
    Investor Relations
    Boston Scientific Corporation

Paul Donovan, +1-508-650-8541 (office), +1-508-667-5165 (mobile), Media Relations, Boston Scientific Corporation; Larry Neumann, +1-508-650-8696 (office), Investor Relations, Boston Scientific Corporation